Investments
502Portfolio Exits
100About Morgenthaler Ventures
Morgenthaler is a leading U.S. venture-capital firm with offices in Menlo Park, California; Boston, Massachusetts; Princeton, New Jersey; Boulder, Colorado and Cleveland, Ohio.

Want to inform investors similar to Morgenthaler Ventures about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Morgenthaler Ventures News
Apr 30, 2023
Relievant Medsystems – a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP) – announced that it has completed the closing of its $50 million Series G financing. The funding was led by new investor Ally Bridge Group with participation from existing investors Endeavour Vision, Vensana Capital, Lightstone Ventures, New Enterprise Associates, Canaan Partners, and Morgenthaler Ventures. There are 30 million people in the U.S. with chronic low back pain and 1 in 6 are likely to have vertebrogenic pain, which is a distinct type of chronic low back pain caused by damage to vertebral endplates, the interface between the disc and the vertebral body. The patients who typically have pain in the middle of their low back, which worsens when they bend over, sit for long periods of time, or when they are active. A physician is able to confirm a patient’s pain is vertebrogenic by observing Modic changes, a biomarker seen on standard MRI that indicates inflammation at the vertebral endplate. Relievant Medsystems’ minimally invasive Intracept Procedure is known as the only FDA-cleared treatment for chronic vertebrogenic low back pain, using targeted radiofrequency energy for stopping the basivertebral nerve (BVN) from transmitting pain signals to the brain. And the procedure is typically performed in an outpatient surgery center and takes about 1 hour. And based on existing data, patients usually experience minimal post-procedure pain and generally quick recovery times. Patients often feel pain relief within 2 weeks of being treated with the Intracept Procedure. KEY QUOTES: “This substantial additional funding allows us to further accelerate our efforts to transform the diagnosis and treatment of vertebrogenic pain. We are thrilled to see strong support from Ally Bridge Group and existing investors in this oversubscribed round as we expand Intracept adoption and make this treatment available to more patients and physicians.” — Tyler Binney, President and CEO of Relievant Medsystems “We are pleased to join the investor syndicate supporting Relievant. We have been impressed by the company’s novel and clinically proven technology and accelerating commercial traction and adoption. We are excited to partner with the company on its journey to provide relief for the millions of patients in the U.S. suffering from chronic low back pain indicated for Relievant’s Intracept Procedure.” — Kevin Reilly, a Managing Director at Ally Bridge Group Trending on Pulse 2.0
Morgenthaler Ventures Investments
502 Investments
Morgenthaler Ventures has made 502 investments. Their latest investment was in Relievant Medsystems as part of their Series G - II on April 4, 2023.

Morgenthaler Ventures Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/19/2023 | Series G - II | Relievant Medsystems | $50M | No | 5 | |
1/19/2023 | Series F | SetPoint Medical | $80M | No | Action Potential Venture Capital, Ascendum Capital, Boston Scientific, Catalio Capital Management, Citta Capital, Euclidean Capital, Gilmartin Capital, Midas Capital, Morgenthaler Ventures, New Enterprise Associates, Norwest Venture Partners, Richard King Mellon Foundation Social-Impact Pitch Competition, Shangbay Capital, SVE Capital, Topspin Fund, Undisclosed Investors, and Viking Global Investors | 5 |
8/16/2022 | Series C - II | Moximed | No | 2 | ||
10/29/2020 | Series G | |||||
2/14/2019 | Series E |
Date | 4/19/2023 | 1/19/2023 | 8/16/2022 | 10/29/2020 | 2/14/2019 |
---|---|---|---|---|---|
Round | Series G - II | Series F | Series C - II | Series G | Series E |
Company | Relievant Medsystems | SetPoint Medical | Moximed | ||
Amount | $50M | $80M | |||
New? | No | No | No | ||
Co-Investors | Action Potential Venture Capital, Ascendum Capital, Boston Scientific, Catalio Capital Management, Citta Capital, Euclidean Capital, Gilmartin Capital, Midas Capital, Morgenthaler Ventures, New Enterprise Associates, Norwest Venture Partners, Richard King Mellon Foundation Social-Impact Pitch Competition, Shangbay Capital, SVE Capital, Topspin Fund, Undisclosed Investors, and Viking Global Investors | ||||
Sources | 5 | 5 | 2 |
Morgenthaler Ventures Portfolio Exits
100 Portfolio Exits
Morgenthaler Ventures has 100 portfolio exits. Their latest portfolio exit was Relievant Medsystems on September 19, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
9/19/2023 | Acquired | 6 | |||
1/3/2023 | Acquired | 4 | |||
11/16/2022 | Acquired | 14 | |||
Date | 9/19/2023 | 1/3/2023 | 11/16/2022 | ||
---|---|---|---|---|---|
Exit | Acquired | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 6 | 4 | 14 |
Morgenthaler Ventures Acquisitions
12 Acquisitions
Morgenthaler Ventures acquired 12 companies. Their latest acquisition was Arisdyne Systems on June 18, 2008.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
6/18/2008 | Debt | $10.85M | Acquired | |||
7/9/2007 | Acquired | |||||
9/19/2006 | Debt | $7.5M | Acquired | |||
7/15/2006 | Series D | |||||
5/19/2006 |
Date | 6/18/2008 | 7/9/2007 | 9/19/2006 | 7/15/2006 | 5/19/2006 |
---|---|---|---|---|---|
Investment Stage | Debt | Debt | Series D | ||
Companies | |||||
Valuation | |||||
Total Funding | $10.85M | $7.5M | |||
Note | Acquired | Acquired | Acquired | ||
Sources |
Morgenthaler Ventures Team
10 Team Members
Morgenthaler Ventures has 10 team members, including current Founding Partner, David Morgenthaler.
Name | Work History | Title | Status |
---|---|---|---|
David Morgenthaler | Founding Partner | Current | |
Name | David Morgenthaler | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Founding Partner | ||||
Status | Current |